Anti-Human TNF alpha Therapeutic Antibody Fab Fragment (Certolizumab Pegol) (CAT#: TAB-034-F(E))

Recombinant antibody Fragment Fab to TNF alpha. Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Polyethylene glycol does not cross the placenta, so it should be safe in pregnancy.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
Activ

Figure 1 Efficacy variables in the certolizumab pegol (CZP) intention-to-treat (ITT) (n = 492) and week-24 CZP completer populations (n = 342).

a Mean disease activity score in 28 joints (erythrocyte sedimentation rate) (DAS28(ESR)). b Mean health assessment questionnaire-disability index (HAQ-DI). c American College of Rheumatologists (ACR)20 response. d ACR50 and ACR70 responses. For patients who withdrew at week 16, observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures, NRI non-responder imputation.

Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.

Activ

Figure 2 Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W (n = 369).

a Mean disease activity score in 8 joints (erythrocyte sedimentation rate) (DAS28(ESR)). bAmerican College of Rheumatology (ACR)20 response rates. c ACR50 and ACR70 response rates. This analysis is presented as weeks following dose-reduction visit (Week 0 is defined as the final efficacy assessment visit where a patient received the CZP 400 mg dose).

Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.

Inhib

Figure 3 Effect of CZP in patients with and without prior TNF inhibitor exposure at week 24 in terms of ACR response and the kinetics of ACR response.

CZP, Certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks; PBO, placebo; TNF, tumour necrosis factor. (A) Percentages of patients with and without prior TNF inhibitor exposure achieving a response according to the American College of Rheumatology Criteria for 20% improvement (ACR20), 50% improvement (ACR50), and 70% improvement (ACR70) at week 24, by treatment group. (B) Percentages of patients with prior TNF inhibitor exposure achieving an ACR20, ACR50, and ACR70 response over time, by treatment group. (C) Percentages of patients without prior TNF inhibitor exposure achieving an ACR20, ACR50 and ACR70 response over time, by treatment group; *p<0.001; †p<0.05 versus placebo.

Mease, P. J., Fleischmann, R., Deodhar, A. A., Wollenhaupt, J., Khraishi, M., Kielar, D.,... & Van Der Heijde, D. (2014). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the rheumatic diseases, 73(1), 48-55.

FuncS

Figure 4 Emotional Function and Systemic Symptoms were the domains that patients reported as being most improved by certolizumab pegol treatment.

Mean change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores during 12 weeks subcutaneous treatment with either certolizumab pegol or placebo in patients with moderate-to-severe Crohn's disease (intent-to-treat population); least-squares means (adjusted for stratum, pooled country, and baseline score): a Bowel Symptoms domain, b Systemic Symptoms domain, c Emotional Function domain, and d Social Function domain.

Rutgeerts, P., Schreiber, S., Feagan, B., Keininger, D. L., O’Neil, L., & Fedorak, R. N. (2008). Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. International journal of colorectal disease, 23(3), 289-296.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • Fab'
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut, IHC, Activ, Inhib
  • Trade name
  • cimzia
  • CAS
  • 428863-50-7
  • Generic Name
  • Certolizumab pegol
  • ATC Code
  • L04AB05
  • ChEMBL
  • CHEMBL1201831
  • MW
  • 47.75 kDa
  • Related Disease
  • Psoriatic arthritis (PSA)

Applications

  • Application Notes
  • The TNF antibody has been reported in applications of ELISA, FC, IP, FuncS, IF, Neut, IHC, Activ, Inhib.

Target

  • Alternative Names
  • Certolizumab pegol;cimzia;428863-50-7;CDP870;PHA-738144;TNF;tumor necrosis factor;TNFA, tumor necrosis factor (TNF superfamily, member 2);DIF;TNF superfamily;member 2;TNF alpha;TNFSF2;TNF-a;cachectin;APC1 protein;TNF, monocyte-derived;TNF, macrophage-deri

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Certolizumab Pegol.

See other products for "TNF"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart